TPI 1020, a novel anti-inflammatory, nitric oxide donating compound, potentiates the bronchodilator effects of salbutamol in conscious guinea-pigs

European Journal of Pharmacology

Volumn 641, Issue 2-3, 2010, Pages 213-219

  Turner, Dawn L ^a   Ferrari, Nicolay ^b   Ford, William R ^a   Kidd, Emma J ^a   Paquet, Luc ^b   Renzi, Paulo ^b   Broadley, Kenneth J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Bronchodilatation; Budesonide; Conscious guinea pig; ODQ; Salbutamol; SNAP; TPI 1020

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ANTIINFLAMMATORY AGENT; BUDESONIDE; BUDESONIDE 21 (4' NITROOXYMETHYL)BENZOATE; HISTAMINE; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE DONOR; SALBUTAMOL; TPI 1020; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHODILATATION; BRONCHODILATING ACTIVITY; BRONCHOSPASM; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EXPERIMENTAL GUINEA PIG; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; BUDESONIDE; CONSCIOUSNESS; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; GUINEA PIGS; HISTAMINE; MALE; NITRIC OXIDE; NITRIC OXIDE DONORS; RECEPTORS, ADRENERGIC, BETA-2; S-NITROSO-N-ACETYLPENICILLAMINE;

EID: 77954089575     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.05.025     Document Type: Article

References (47)

1. Adler K.B., Fischer B.M., Li H., Choe N.H., Wright D.T. Hypersecretion of mucin in response to inflammatory mediators by guinea pig tracheal epithelial cells in vitro is blocked by inhibition of nitric oxide synthase. Am. J. Respir. Cell Mol. Biol. 1995, 13:526-530.
2. Anderson P.J., Zhou X., Breen P., Gann L., Logsdon T.W., Compadre C.M., Hiller F.C. Pharmacokinetics of (R, S)-albuterol after aerosol inhalation in healthy adult volunteers. J. Pharm. Sci. 1998, 87:841-844.
3. Banner H.H., Press N.J. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br. J. Pharmacol. 2009, 157:892-906.
4. Barnes P.J., Adcock I.M. Glucocorticoid resistance in inflammatory diseases. Lancet 2009, 373:1905-1917.
5. Bateman E.D., Hurd S.S., Barnes P.J., Bousquet J., Drazen J.M., FitzGerald M., et al. Global strategy for asthma management and prevention: Gina executive summary. Eur. Respir. J. 2008, 31:143-178.
6. Belvisi M.G., Stretton C.D., Yacoub M., Barnes P.J. Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans. Eur. J. Pharmacol. 1992, 210:221-222.
7. Bousquet J., Jeffery P.K., Busse W.W., Johnson M., Vignola A.M. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am. J. Respir. Crit. Care Med. 2000, 161:1720-1745.
8. Brodde O.E., Howe U., Egerszegi S., Konietzko N., Michel M.C. Effect of prednisolone and ketotifen on beta 2-adrenoceptors in asthmatic patients receiving beta 2-bronchodilators. Eur. J. Clin. Pharmacol. 1988, 34:145-150.
9. Carstairs J.R., Nimmo A.J., Barnes P.J. Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am. Rev. Respir. Dis. 1985, 132:541-547.
10. Davies N.M., Roseth A.G., Appleyard C.B., McKnight W., Del Soldato P., Calignano A. NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment. Pharmacol. Ther. 1997, 11:69-79.
11. de Boer J., Philpott A.J., van Amsterdam R.G., Shahid M., Zaagsma J., Nicholson C.D. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br. J. Pharmacol. 1992, 106:1028-1034.
12. Dupuy P.M., Shore S.A., Drazen J.M., Frostell C., Hill W.A., Zapol W.M. Bronchodilator action of inhaled nitric oxide in guinea pigs. J. Clin. Invest. 1992, 90:421-428.
13. El Kebir D., Hubert B., Taha R., Troncy E., Wang T., Gauvin D. Effects of inhaled nitric oxide on inflammation and apoptosis after cardiopulmonary bypass. Chest 2005, 128:2910-2917.
14. Fiorucci S., Santucci L., Antonelli E., Distrutti E., Del Sero G., Morelli O. NO-aspirin protects from T cell-mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines. Gastroenterology 2000, 118:404-421.
15. Fiorucci S., Antonelli E., Distrutti E., Del Soldato P., Flower R.J., Clark M.J. NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T Cells in the lamina propria and protects against 2, 4, 6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc. Natl Acad. Sci. USA 2002, 99:15770-15775.
16. Garthwaite J., Southam E., Boulton C.L., Nielsen E.B., Schmidt K., Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1, 2, 4]Oxadiazolo[4, 3-a]quinoxalin-1-one. Mol. Pharmacol. 1995, 48:184-188.
17. Griffiths-Johnson D.A., Nicholls P.J., McDermott M. Measurement of specific airway conductance in guinea pigs. A noninvasive method. J. Pharmacol. Meth. 1988, 19:233-242.
18. Harris J.B., Ahrens R.C., Milavetz G., Annis L., Ries R., Hendricker C. Comparison of the intensity and duration of effects of inhaled bitoterol and albuterol on airway caliber and airway responsiveness to histamine. J. Allergy Clin. Immunol. 1990, 85:1043-1049.
19. Henriksen J.M., Agertoft L., Pedersen S. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. J. Allergy Clin. Immunol. 1992, 89:1176-1182.
20. Hjoberg J., Hogman M., Hedenstierna G. Hyperosmolarity reduces the relaxing potency of nitric oxide donors in guinea-pig trachea. Br. J. Pharmacol. 1999, 127:391-396.
21. Horvath G., Mendes E.S., Schmid N., Schmid A., Conner G.E., Salathe M. The Effect of corticosteroids on the disposal of long-acting beta2-agonists by airway smooth muscle cells. J. Allergy Clin. Immunol. 2007, 120:1103-1109.
22. Kassel K.M., Wyatt T.A., Panettieri R.A., Toews M.L. Inhibition of human airway smooth muscle cell proliferation by beta 2-adrenergic receptors and cAMP is PKA-independent: evidence for EPAC involvement. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 294:L131-L138.
23. Ketchell R.I., Jensen M.W., Lumley P., Wright A.M., Allenby M.I., O'Connor B.J. Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5′-monophosphate in mild asthma. J. Allergy Clin. Immunol. 2002, 110:603-606.
24. Kirstein M., Rivet-Bastide M., Hatem S., Benardeau A., Mercadier J.J., Fischmeister R. Nitric oxide regulates the calcium current in isolated human atrial myocytes. J. Clin. Invest. 1995, 95:794-802.
25. Leifer K.N., Wittig H.J. Ann. Allergy 1975, 35:69-80.
26. Lipworth B.J. Airway and systemic effects of inhaled corticosteroids in asthma: Dose response relationship. Pulm. Pharmacol. 1996, 9:19-27.
27. Mak J.C., Nishikawa M., Barnes P.J. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. Am. J. Physiol. 1995, 268:L41-L46.
28. Mohammed S.P., Taylor C.V., Weyman-Jones C.B., Mather M.E., Vendy K., Dougall I.G., Young A. Duration of action of inhaled vs. intravenous beta(2)-adrenoceptor agonists in an anaesthetized guinea-pig model. Pulm. Pharmacol. Ther. 2000, 13:287-292.
29. Nevin B.J., Broadley K.J. Comparative effects of inhaled budesonide and the NO-donating budesonide derivative, NCX 1020, against leukocyte influx and airway hyperreactivity following lipopolysaccharide challenge. Pulm. Pharmacol. Ther. 2004, 17:219-232.
30. Nials A.T., Sumner M.J., Johnson M., Coleman R.A. Investigations into factors determining the duration of action of the beta 2-adrenoceptor agonist, salmeterol. Br. J. Pharmacol. 1993, 108:507-515.
31. Nials A.T., Coleman R.A., Johnson M., Magnussen H., Rabe K.F., Vardey C.J. Effects of beta-adrenoceptor agonists in human bronchial smooth muscle. Br. J. Pharmacol. 1993, 110:1112-1116.
32. O'Connor B.J., Crowther S.D., Costello J.F., Morley J. Selective airway responsivenes in asthma. Trends Pharmacol. Sci. 1999, 20:9-11.
33. Paul-Clark M., Del Soldato P., Fiorucci S., Flower R.J., Perretti M. 21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti-inflammatory properties. Br. J. Pharmacol. 2000, 131:1345-1354.
34. Paul-Clark M.J., Mancini L., Del Soldato P., Flower R.J., Perretti M. Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc. Natl Acad. Sci. USA 2002, 99:1677-1682.
35. Paul-Clarke M.J., Roviezzo F., Flower R.J., Cirino G., Soldato P.D., Adcock I.M., Perretti M. Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. J. Immunol. 2003, 171:3245-3252.
36. Robison G.A., Butcher R.W., Sutherland E.W. Adenyl cyclase as an adrenergic receptor. Ann. NY Acad. Sci. 1967, 139:703-723.
37. Rodrigo G.J. Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation. Chest 2006, 130:1301-1311.
38. Rodrigo G., Rodrigo C. Inhaled flunisolide for acute severe asthma. Am. J. Respir. Crit. Care Med. 1998, 157:698-703.
39. Sandner P., Kornfeld M., Ruan X., Arendshorst W.J., Kurtz A. Nitric oxide/cAMP interactions in the control of rat renal vascular resistance. Circ. Res. 1999, 84:186-192.
40. Silver P.J., Hamel L.T., Perrone M.H., Bentley R.G., Bushover C.R., Evans D.B. Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur. J. Pharmacol. 1988, 150:85-94.
41. Smith N., Broadley K.J. Optimisation of the sensitisation conditions for an ovalbumin challenge model of asthma. Int. J. Immunopharmacol. 2007, 7:183-190.
42. Tallet D., Del Soldato P., Oudart N., Burgaud J.L. NO-steroids: potent anti-inflammatory drugs with bronchodilating activity in vitro. Biochem. Biophys. Res. Commun. 2002, 290:125-130.
43. Tan K.S., Grove A., McLean A., Gnosspelius Y., Hall I.P., Lipworth B.J. Systemic corticosteroid rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am. J. Respir. Crit. Care Med. 1997, 156:28-35.
44. Toward T.J., Lewis-Lakelin M.B., Burgaud J.-L., Broadley K.J. Comparison of the inhibition by salbutamol-NO and salbutamol of the bronchoconstriction by histamine in conscious guinea-pigs. Inflamm. Res. 2001, 50(Suppl 3):S181.
45. Wallace J.L., Zamuner S.R., McKnight W., Dicay M., Mencarelli A., del Soldato P. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. Am. J. Physiol. 2004, 286:G76-G81.
46. Ward J.K., Barnes P.J., Tadjkarimi S., Yacoub M.H., Belvisi M.G. Evidence for the involvement of cGMP in neural bronchodilator responses in human trachea. J. Physiol. 1995, 483(Pt 2):525-536.
47. Wenzel S. Mechanisms of severe asthma. Clin. Exp. Allergy 2003, 33:1622-1628.